DD248057A5 - Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-/imino/2-(2-methoxyethoxy)ethyliden/-oxy/-9s)-erythromycin und verfahren zu ihrer herstellung - Google Patents
Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-/imino/2-(2-methoxyethoxy)ethyliden/-oxy/-9s)-erythromycin und verfahren zu ihrer herstellung Download PDFInfo
- Publication number
- DD248057A5 DD248057A5 DD86292273A DD29227386A DD248057A5 DD 248057 A5 DD248057 A5 DD 248057A5 DD 86292273 A DD86292273 A DD 86292273A DD 29227386 A DD29227386 A DD 29227386A DD 248057 A5 DD248057 A5 DD 248057A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- active ingredient
- basic
- preparation
- dosage forms
- intimate mixture
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 20
- 238000000034 method Methods 0.000 title claims description 16
- -1 IMINO Chemical class 0.000 title claims description 11
- 229960003276 erythromycin Drugs 0.000 title claims description 8
- 239000007787 solid Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 2
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 title 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 40
- 239000002671 adjuvant Substances 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 14
- 239000011872 intimate mixture Substances 0.000 claims abstract description 14
- 239000013543 active substance Substances 0.000 claims abstract description 10
- 239000000853 adhesive Substances 0.000 claims abstract description 7
- 230000001070 adhesive effect Effects 0.000 claims abstract description 7
- 239000002702 enteric coating Substances 0.000 claims abstract description 7
- 238000009505 enteric coating Methods 0.000 claims abstract description 7
- 239000000155 melt Substances 0.000 claims abstract description 7
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 6
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 4
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 3
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 239000008188 pellet Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000004922 lacquer Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 10
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 8
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 7
- 239000002966 varnish Substances 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000920 calcium hydroxide Substances 0.000 claims description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 3
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 claims description 3
- 239000002370 magnesium bicarbonate Substances 0.000 claims description 3
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 claims description 3
- 235000014824 magnesium bicarbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000005453 pelletization Methods 0.000 claims 1
- 239000012798 spherical particle Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000005923 long-lasting effect Effects 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- WLOHNSSYAXHWNR-DWIOZXRMSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-DWIOZXRMSA-N 0.000 description 30
- 230000000968 intestinal effect Effects 0.000 description 27
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
- 210000004051 gastric juice Anatomy 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000036765 blood level Effects 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000002360 explosive Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- XCLJRCAJSCMIND-JCTYMORFSA-N (9S)-erythromycyclamine Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)[C@@H](N)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XCLJRCAJSCMIND-JCTYMORFSA-N 0.000 description 3
- 229920003136 Eudragit® L polymer Polymers 0.000 description 3
- 229920003137 Eudragit® S polymer Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229960002380 dibutyl phthalate Drugs 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- SYFMDCRSOXZKQO-UHFFFAOYSA-N acetic acid;dibutyl benzene-1,2-dicarboxylate;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O.CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC SYFMDCRSOXZKQO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940104746 magnesium carbonate 100 mg Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853524572 DE3524572A1 (de) | 1985-07-10 | 1985-07-10 | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD248057A5 true DD248057A5 (de) | 1987-07-29 |
Family
ID=6275375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD86292273A DD248057A5 (de) | 1985-07-10 | 1986-07-08 | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-/imino/2-(2-methoxyethoxy)ethyliden/-oxy/-9s)-erythromycin und verfahren zu ihrer herstellung |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4755385A (fr) |
| EP (1) | EP0208971B1 (fr) |
| JP (1) | JPH0688905B2 (fr) |
| KR (1) | KR930010586B1 (fr) |
| AT (1) | ATE63819T1 (fr) |
| AU (1) | AU586262B2 (fr) |
| CA (1) | CA1271138A (fr) |
| DD (1) | DD248057A5 (fr) |
| DE (2) | DE3524572A1 (fr) |
| DK (1) | DK165670C (fr) |
| ES (1) | ES2000269A6 (fr) |
| FI (1) | FI85649C (fr) |
| GR (1) | GR861762B (fr) |
| HK (1) | HK79791A (fr) |
| HU (1) | HU195730B (fr) |
| IE (1) | IE58951B1 (fr) |
| IL (1) | IL79375A (fr) |
| MX (1) | MX9202785A (fr) |
| NL (1) | NL970004I2 (fr) |
| NO (1) | NO175351C (fr) |
| NZ (1) | NZ216794A (fr) |
| PH (1) | PH26147A (fr) |
| PT (1) | PT82949B (fr) |
| SG (1) | SG72191G (fr) |
| ZA (1) | ZA865105B (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
| US4945080A (en) * | 1987-05-26 | 1990-07-31 | Eli Lilly And Company | Dirithromycin metabolite |
| US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
| ZA922777B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical formulation containing dirithromycin |
| US5556839A (en) * | 1991-04-29 | 1996-09-17 | Eli Lilly And Company | Form II Dirithromycin |
| IT1250701B (it) * | 1991-07-24 | 1995-04-21 | Angelini Francesco Ist Ricerca | Composizione farmaceutica solida per uso orale a base di dapiprazolo |
| HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| IT1256386B (it) * | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
| JP4040084B2 (ja) * | 1994-02-16 | 2008-01-30 | アボツト・ラボラトリーズ | 微粒子医薬調合物の調製プロセス |
| MX9605419A (es) * | 1994-05-06 | 1997-12-31 | Pfizer | Formas de dosificacion de liberacion controlada de azitromicina. |
| US5853787A (en) * | 1995-12-22 | 1998-12-29 | Tamer International | Method for reducing coffee acidity |
| US6045843A (en) * | 1995-12-22 | 2000-04-04 | Tamer International, Inc. | Acid-reduced, whole bean coffee process |
| US6495180B1 (en) | 1995-12-22 | 2002-12-17 | Tamer International, Ltd. | Acid reduced whole bean coffee and process |
| US6066342A (en) * | 1995-12-22 | 2000-05-23 | Tamer International, Ltd. | Antacid composition |
| BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US6582708B1 (en) | 2000-06-28 | 2003-06-24 | The Procter & Gamble Company | Tooth whitening substance |
| US20020018754A1 (en) * | 1999-03-15 | 2002-02-14 | Paul Albert Sagel | Shapes for tooth whitening strips |
| US6096328A (en) | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
| PT1187601E (pt) * | 1999-06-07 | 2005-11-30 | Altana Pharma Ag | Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido |
| DE19925710C2 (de) * | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
| USRE42126E1 (en) | 1999-07-02 | 2011-02-08 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
| EP1118321A1 (fr) * | 2000-01-14 | 2001-07-25 | Ucb, S.A. | Compositions pharmaceutiques solides pour la libération contrôlée de substances actives |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| MXPA03000082A (es) * | 2000-06-28 | 2004-07-08 | Procter & Gamble | Estructuras y composiciones que aumentan la estabilidad de los ingredientes activos de peroxido. |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| US6949240B2 (en) * | 2002-05-23 | 2005-09-27 | The Procter & Gamble Company | Tooth whitening products |
| US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
| AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004258949B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004258944B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004264939A1 (en) | 2003-08-11 | 2005-02-24 | Middlebrook Pharmaceuticals, Inc. | Robust pellet |
| CA2535398C (fr) | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotique, utilisation et formulation associees |
| CA2535780A1 (fr) | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Produit antibiotique, son utilisation et sa formulation |
| AU2004273830B2 (en) | 2003-09-15 | 2011-03-24 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| EP1771158A4 (fr) | 2004-07-02 | 2008-03-12 | Advancis Pharmaceutical Corp | Comprimé pour distribution par impulsion |
| US9205054B2 (en) | 2005-03-22 | 2015-12-08 | Losan Pharma Gmbh | Solubilized ibuprofen |
| EP1916995B2 (fr) * | 2005-07-29 | 2022-06-29 | Stichting Groningen Centre for Drug Research | Système de distribution pulsatile commandé par le ph, procédés de préparation et utilisation |
| JP2009515993A (ja) * | 2005-11-17 | 2009-04-16 | ノバルティス アクチエンゲゼルシャフト | 医薬組成物 |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| TW200800233A (en) * | 2006-04-28 | 2008-01-01 | Shionogi & Amp Co Ltd | A coated preparation of macrolide antibiotics |
| US8299052B2 (en) * | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| US10285915B2 (en) | 2012-10-17 | 2019-05-14 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
| GB2533593A (en) * | 2014-12-22 | 2016-06-29 | Parkside Flexibles (Europe) Ltd | Package |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3081233A (en) * | 1960-08-08 | 1963-03-12 | Upjohn Co | Enteric-coated pilules |
| US4000254A (en) * | 1966-04-25 | 1976-12-28 | Schmid Laboratories, Inc. | Fungimycin compositions |
| US3784683A (en) * | 1971-03-29 | 1974-01-08 | Abbott Lab | Tablet preparation |
| US3865935A (en) * | 1972-08-10 | 1975-02-11 | Abbott Lab | Tableting of erythromycin base |
| US3891755A (en) * | 1973-07-11 | 1975-06-24 | Abbott Lab | Dosage formulation for erythromycin cetyl sulfate |
| AT342770B (de) * | 1975-04-07 | 1978-04-25 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer erythromycinderivate |
| US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
| JPS5840529B2 (ja) * | 1975-09-29 | 1983-09-06 | 明治製菓株式会社 | ケイコウヨウセイザイノセイホウ |
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| US4340582A (en) * | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
| JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
-
1985
- 1985-07-10 DE DE19853524572 patent/DE3524572A1/de not_active Withdrawn
-
1986
- 1986-06-27 DE DE8686108791T patent/DE3679463D1/de not_active Expired - Lifetime
- 1986-06-27 EP EP86108791A patent/EP0208971B1/fr not_active Expired - Lifetime
- 1986-06-27 AT AT86108791T patent/ATE63819T1/de active
- 1986-07-07 GR GR861762A patent/GR861762B/el unknown
- 1986-07-08 CA CA000513268A patent/CA1271138A/fr not_active Expired - Lifetime
- 1986-07-08 DK DK324786A patent/DK165670C/da not_active IP Right Cessation
- 1986-07-08 KR KR1019860005492A patent/KR930010586B1/ko not_active IP Right Cessation
- 1986-07-08 DD DD86292273A patent/DD248057A5/de not_active IP Right Cessation
- 1986-07-08 US US06/882,999 patent/US4755385A/en not_active Expired - Lifetime
- 1986-07-09 HU HU862853A patent/HU195730B/hu unknown
- 1986-07-09 NO NO862772A patent/NO175351C/no not_active IP Right Cessation
- 1986-07-09 ZA ZA865105A patent/ZA865105B/xx unknown
- 1986-07-09 JP JP61159913A patent/JPH0688905B2/ja not_active Expired - Lifetime
- 1986-07-09 IL IL79375A patent/IL79375A/xx not_active IP Right Cessation
- 1986-07-09 NZ NZ216794A patent/NZ216794A/xx unknown
- 1986-07-09 AU AU59876/86A patent/AU586262B2/en not_active Expired
- 1986-07-09 ES ES8600197A patent/ES2000269A6/es not_active Expired
- 1986-07-09 IE IE184286A patent/IE58951B1/en not_active IP Right Cessation
- 1986-07-09 PT PT82949A patent/PT82949B/pt unknown
- 1986-07-10 FI FI862898A patent/FI85649C/fi not_active IP Right Cessation
- 1986-07-11 PH PH34006A patent/PH26147A/en unknown
-
1991
- 1991-08-26 SG SG721/91A patent/SG72191G/en unknown
- 1991-10-10 HK HK797/91A patent/HK79791A/xx not_active IP Right Cessation
-
1992
- 1992-06-11 MX MX9202785A patent/MX9202785A/es unknown
-
1997
- 1997-01-31 NL NL970004C patent/NL970004I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0208971B1 (fr) | Formes galéniques solides pour application orale contenant de la 9-déoxo-11-déoxy-9,11-(imino(2-(2-méthoxyéthoxy)éthylidène)-oxy-)-(9S)-érythromycine et leur procédé de préparation | |
| EP0068191B1 (fr) | Formes orales du dipyridamole | |
| EP0720473B1 (fr) | Pellets de budesonide a liberation controlee et leur procede de preparation | |
| EP0108898B1 (fr) | Formes galéniques orales de mopidamol | |
| EP0069259B1 (fr) | Forme retard de bromhexine et procédé de préparation | |
| EP0032562B1 (fr) | Formes-retard pour l'administration du dipyridamol et procédés pour leur préparation | |
| DE3587274T2 (de) | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. | |
| EP0925060B2 (fr) | Pastilles se decomposant rapidement | |
| DE69230112T2 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| DE69205971T2 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
| DE69208299T2 (de) | Feste Arzneizubereitungen zur oralen Verabreichung mit verlängerter Magenverweilzeit | |
| DE69630286T2 (de) | Aus mehreren einzeleinheiten zusammengesetzte dosierungsformen enthaltend einem protonen pumpen inhibitor | |
| DE60103299T2 (de) | Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe | |
| AT398166B (de) | Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung von nitrofurantoin (-salzen, -hydraten, -komplexen) | |
| DE1093050B (de) | Verfahren zur Herstellung einer Penicillintablette mit verlaengerter Wirkung | |
| EP0250648B1 (fr) | Préparation pharmaceutique pour la libération retardée de l'ibuprofène | |
| DD298205A5 (de) | Verfahren zum herstellen von langzeitwirkenden arzneimittelzubereitungen | |
| WO2005117896A1 (fr) | Formulations contenant du fasudil, une matrice et une enveloppe | |
| EP1017392B1 (fr) | Formulation medicamenteuse a liberation controlee du principe actif | |
| EP0306699A1 (fr) | Préparation retard de dihydropyridines | |
| EP2415460A1 (fr) | Formulations pour l'administration orale de prégabaline | |
| DE10153934A1 (de) | Verfahren zur Kristallisation von Profenen | |
| DE19850445A1 (de) | Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen | |
| WO1999058107A2 (fr) | Preparation orale ou mucosique contenant un principe actif, a liberation regulable du principe actif et son utilisation | |
| DE1467919C (de) | Verwendung des Aluminiumsalzes der O-Acetylsalicylsäure in festen Arzneizubereitungsformen mit Depot-Wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |